Primary Risk Drivers
Below is a snapshot of domains that materially influence the MARA Rating.
Clinical effectiveness
The evidence from the CheckMate 649 trial demonstrates that nivolumab plus platinum- and fluoropyrimidine-based chemotherapy significantly improves both progression-free survival and overall survival compared to chemotherapy alone, with hazard ratios of 0.70 for both outcomes. This indicates a clear clinical advantage over standard care.
Cost effectiveness
The cost-effectiveness estimates for nivolumab are reported to be within acceptable thresholds, with ICERs comfortably below £50,000 per QALY gained in the most plausible scenarios. This indicates that the treatment is marginally cost-effective.
Quality of life
While the document highlights the significant impact of gastric cancer on quality of life, it does not provide specific HRQoL data from validated instruments. However, the potential for improved survival and the reduction of distressing symptoms suggest a moderate benefit in HRQoL.
Supporting Domains
Safety and Adverse Effects
The safety profile of nivolumab is described as acceptable, with manageable adverse events. The document indicates that adverse effects are mostly mild to moderate, supporting a very good tolerability rating.
Comparator Selection
Nivolumab was compared against appropriate standard-of-care treatments (XELOX and FOLFOX), which are the most relevant comparators for this patient population. This ideal head-to-head comparison strengthens the evidence base.
Patient Population and Subgroups
The trial population is generally representative of the intended patient population, although there are some concerns regarding age and fitness levels. However, the core population is adequately covered, supporting a moderate rating.
Care Pathway Integration
Nivolumab can be integrated into existing treatment pathways with manageable adjustments, as it is used in combination with standard chemotherapy regimens. This indicates a good fit with current clinical practice.
Resource Use and Cost Implications
The economic model suggests that the budget impact is manageable and aligns with Healthcare planning, indicating that the resource use is justifiable given the treatment’s benefits.
Evidence Quality and Robustness
The evidence is based on a robust Phase III RCT (CheckMate 649) with a large sample size and mature data, which supports the credibility and reliability of the findings.
Uncertainty, Sensitivity, and Broader Impacts
While the treatment shows promise, there are significant uncertainties regarding long-term survival and treatment effect waning, which could impact decision-making. This leads to a moderate risk rating.
